REFERENCES
1. Bulun S.E., Yilmaz B.D., Sison C., Miyazaki K., Bernardi L., Liu S., et al. Endometriosis. Endocr Rev. 2019; 40: 1048-79.
2. Tian Z., Zhang Y., Zhang C., Wang Y., Zhu H.L. Antral follicle count is reduced in the presence of endometriosis: a systematic review and metaanalysis. Reprod Biomed Online. 2021; 42: 237-47.
3. Simon C., Gutierrez A., Vidal A., de los Santos M.J., Tarlh J.J., Remohf J., et al. Outcome of patients with endometriosis in assisted reproduction: results from in-vitro fertilization and oocyte donation. Hum Reprod. 1994; 9: 725-9.
4. Orazov M.R., Radzinsky V.Y., Ivanov I.I., Khamoshina M.B., Shus-tova V.B. Oocyte quality in women with infertility associated endometriosis. Gynecol Endocrinol. 2019; 35 (suppl 1): 24-6.
5. Senapati S., Sammel M.D., Morse C., Barnhart K.T. Impact of endometriosis on in vitro fertilization outcomes: an evaluation of the Society for Assisted Reproductive Technologies Database. Fertil Steril. 2016; 106: 164-71.e1.
6. Feichtinger M., Nordenhok E., Olofsson J.I., Hadziosmanovic N., Rodriguez-Wallberg K.A. Endometriosis and cumulative live birth rate after fresh and frozen IVF cycles with single embryo transfer in young women: no impact beyond reduced ovarian sensitivity - a case control study. J Assist Reprod Genet. 2019; 36: 1649-56.
7. Vitale S.G., La Rosa V.L., Rapisarda A.M.C., Lagana A.S. Impact of endometriosis on quality of life and psychological well-being. J Psy-chosom Obstet Gynaecol. 2017; 38: 317-9.
8. Brooks T., Sharp R., Evans S., Baranoff J., Esterman A. Predictors of psychological outcomes and the effectiveness and experience of psychological interventions for adult women with chronic pelvic pain: a scoping review. J Pain Res. 2020; 13: 1081-102.
9. Chapron C., Marcellin L., Borghese B., Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019; 15: 666-82.
10. Van Niekerk L., Weaver-Pirie B., Matthewson M. Psychological interventions for endometriosis-related symptoms: a systematic review with narrative data synthesis. Arch Womens Ment Health. 2019; 22: 723-35.
11. Vercellini P., Buggio L., Berlanda N., Barbara G., Somigliana E., Bo-sari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016; 106: 1552-71.e2.
12. Dunselman G.A., Vermeulen N., Becker C., Calhaz-Jorge C., D'Hooghe T., De Bie B., et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29: 400-12.
13. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014; 101: 927-35.
14. Denny E., Weckesser A., Jones G., Bibila S., Daniels J., Bhat-tacharya S.; PRE-EMPT Team. Women's experiences of medical treatment for endometriosis and its impact on PRE-EMPT trial participation: a qualitative study. Pilot Feasibility Stud. 2018; 4: 168.
15. Schweppe K.-W. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009; 65 (suppl 1): S23-7.
16. Bitzer J. Progestogens in Contraception. In: Carp H. (ed.). Proges-togens in Obstetrics and Gynecology. Switzerland: Springer International Publishing, 2015: 111-27.
17. Griesinger G., Tournaye H., Macklon N., Petraglia F., Arck P., Blockeel C., et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019; 38: 249-59.
18. Colombo D., Ferraboschi P., Prestileo P., Toma L. A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy. J Steroid Biochem Mol Biol. 2006; 98: 56-62.
19. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqua-lini J.R., Schweppe K.W., et al. Classification and pharmacology of progestins. Maturitas. 2003; 46 (suppl 1): S7-16.
20. Rizner T.L., Brozic P., Doucette C., Turek-Etienne T., Muller-Vieira U., Sonneveld E., et al. Selectivity and potency of the retroproges-terone dydrogesterone in vitro. Steroids. 2011; 76: 607-15.
21. Stanczyk F.Z., Hapgood J.P., Winer S., Mishell D.R. Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34: 171-208.
22. Griesinger G., Blockeel C., Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? Fertil Steril. 2018; 109: 756-62.
23. Trivedi P., Selvaraj K., Mahapatra P.D., Srivastava S., Malik S. Effective post-laparoscopic treatment of endometriosis with dydrogesterone. Gynecol Endocrinol. 2007; 23 (suppl 1): 73-6.
24. Mirza F.G., Patki A., Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016; 32: 97-106.
25. Abbott B.V., the Netherlands. Duphaston 10 mg film-coated tablets. Summary of Product Characteristics, 2020.
26. Vincent K., Kennedy S., Stratton P. Pain scoring in endometriosis: entry criteria and outcome measures for clinical trials. Report from the Art and Science of Endometriosis meeting. Fertil Steril. 2010; 93: 62-7.
27. Austin P.C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011; 46: 399-424.
28. Bassi M.A., Podgaec S., Dias J.A., Jr, D'Amico Filho N., Petta C.A., Abrao M.S. Quality of life after segmental resection of the rectosigmoid by laparoscopy in patients with deep infiltrating endometriosis with bowel involvement. J Minim Invasive Gynecol. 2011; 18: 730-3.
29. Bourdel N., Alves J., Pickering G., Ramilo I., Roman H., Canis M. Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update. 2015; 21: 136-52.
30. Chopin N., Vieira M., Borghese B., Foulot H., Dousset B., Coste J., et al. Operative management of deeply infiltrating endometriosis: results on pelvic pain symptoms according to a surgical classification. J Minim Invasive Gynecol. 2005; 12: 106-12.
31. Rothrock J.F., Adams A.M., Lipton R.B., Silberstein S.D., Jo E., Zhao X., et al.; FORWARD Study Investigative Group. FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxin A and topiramate for headache prevention in adults with chronic migraine. Headache. 2019; 59: 1700-13.
32. Shao J., Jordan D.C., Pritchett Y.L. Baseline observation carry forward: reasoning, properties, and practical issues. J Biopharm Stat. 2009; 19: 672-84.
33. Hodgson R.M., Lee H.L., Wang R., Mol B.W., Johnson N. Interventions for endometriosis-related infertility: a systematic review and network meta-analysis. Fertil Steril. 2020; 113: 374-82.e2.
34. Harada T., Momoeda M., Taketani Y., Hoshiai H., Terawaka N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008; 90 (5): 1583-8.
35. Johnston W.I. Dydrogesterone and endometriosis. Br J Obstet Gynaecol. 1976; 83: 77-80.
36. Kaiser E., Wagner Th.A. Die behandlung der endometriose mit dy-drogesteron. TW Gynakologie. 1989; 2: 386-8.
37. Walker S.M. The treatment of endometriosis with dydrogesterone. Br J Clin Pract. 1983; 24 (suppl): 40-6.
38. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370: 1453-7.
39. Johnson N.P., Hummelshoj L.; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013; 28: 1552-68.
40. Bedaiwy M.A., Allaire C., Alfaraj S. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017; 107: 537-48.
41. Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017; 107: 533-6.
42. Murji A., Biberoglu K., Leng J., Mueller M.D., Romer T., Vignali M., et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020; 36: 895-907.
43. Moehner S., Becker K., Lange J.A., von Stockum S., Heinemann K. Risk of depression and anemia in users of hormonal endometriosis treatments: results from the VIPOS study. Eur J Obstet Gynecol Reprod Biol. 2020; 251: 212-7.
44. Nirgianakis K., Vaineau C., Agliati L., McKinnon B., Gasparri M.L., Mueller M.D. Risk factors for non-response and discontinuation of dienogest in endometriosis patients: a cohort study. Acta Obstet Gynecol Scand. 2021; 100: 30-40.
45. Brown J., Crawford T.J., Datta S., Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2018; 5: CD001019.
46. Sagsveen M., Farmer J.E., Prentice A., Breeze A. Gonadotrophinreleasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003; 4: CD001297.
47. Donnez J., Taylor H.S., Taylor R.N., Akin M.D., Tatarchuk T.F., Wilk K., et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020; 114: 44-55.
48. Osuga Y., Seki Y., Tanimoto M., Kusumoto T., Kudou K., Terakawa N. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2021; 115: 397-405.
49. Paulson R.J. At last, an orally active gonadotropin-releasing hormone antagonist. Fertil Steril. 2019; 111: 30-1.
50. Taylor H.S., Dun E.C., Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Manag. 2019; 9: 497-515.
51. Podzolkova N., Tatarchuk T., Doshchanova A., Eshimbetova G., Pexman-Fieth C. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol. 2016; 32: 246-9.
52. Trivedi N., Chauhan N., Vaidya V. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study. Gynecol Endocrinol. 2016; 32: 667-71.
53. Arab H., Alharbi A.J., Oraif A., Sagr E., Al Madani H., Abduljab-bar H., et al. The role of progestogens in threatened and idiopathic recurrent miscarriage. Int J Womens Health. 2019; 11: 589-96.
54. Lee H.J., Park T.C., Kim J.H., Norwitz E., Lee B. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. Biomed Res Int. 2017; 2017: 3616875.
55. Saccone G., Schoen C., Franasiak J.M., Scott R.T. Jr, Berghella V. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017; 107: 430-8.e3.
56. Li J., Hong X., Mesiano S., Muglia L.J., Wang X., Snyder M., et al. Natural selection has differentiated the progesterone receptor among human populations. Am J Hum Genet. 2018; 103: 45-57.
57. Reis F.M., Coutinho L.M., Vannuccini S., Batteux F., Chapron C., Pe-traglia F. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020; 26: 565-85.
58. Zeberg H., Kelso J., Paabo S. The neandertal progesterone receptor. Mol Biol Evol. 2020; 37: 2655-60.